Mylan Inc. settled allegations for $465 million it knowingly underpaid rebates owed to the Medicaid program for EpiPen products, officials said Friday.
The products involve injections containing epinephrine, a chemical that narrows blood vessels and opens airways in the lungs. These effects can reverse severe or sometimes life-threatening conditions including low blood pressure, wheezing, severe skin itching, hives and other symptoms of an allergic reaction.
EpiPen’s makers have been under fire for price increases of more than 450 percent for medicines that children and others need.
The settlement arises from False Claims Act litigation involving, among other parties, Ven-a-Care of the Florida Keys Inc.